Acute-phase lipid profile and coronary and treatment outcomes in children with Kawasaki disease: a single-center cohort dataset, Wuhan, China, 2013–2025

Of 7371 children in the source cohort, 6882 with a documented fever-onset date and index intravenous immunoglobulin (IVIG) treatment formed the analytic cohort; 3805 had a lipid panel during the index admission, and 2178 whose first panel was reported before the first IVIG infusion constituted the primary analysis set.The dataset contains: (1) demographic and clinical characteristics (age, sex, weight, incomplete KD status, calendar year, fever-onset date); (2) timing variables that align each measurement to the illness day at blood draw and to the start of the first IVIG infusion; (3) laboratory measures—total cholesterol, triglycerides, HDL cholesterol (HDL-C) and LDL cholesterol (LDL-C) for all tested children, and apolipoprotein A1, apolipoprotein B and lipoprotein(a) in a subset—together with acute-phase markers (high-sensitivity C-reactive protein, white blood cell count, platelet count, albumin, sodium, hemoglobin, alanine aminotransferase, total bilirubin); lipid panels were measured on a Roche cobas c 701 analyzer with enzymatic and direct homogeneous assays; (4) adjudicated coronary outcomes graded normal, dilation only (maximum Z score 2.0 to <2.5), or aneurysm-level involvement (Z ≥2.5 or reported aneurysm), reviewed by cardiologists blinded to laboratory data; and IVIG resistance (persistent or recrudescent fever at least 36 hours after the initial infusion requiring retreatment); and (5) Kobayashi score components.